Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01461538

Study Title
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies (NCT01461538)

Trial Description
This is an open-label, multicenter, phase II clinical trial to evaluate the antitumor activity of the antibody-drug conjugate (ADC) brentuximab vedotin (also known as SGN-035) as a single agent in patients with CD30-positive nonlymphomatous malignancies.

This trial is sponsored by Seattle Genetics. [1]

Study Data

  • Condition: Nonlymphomatous Malignancies
  • Interventions:
  • Phase: II
  • Enrollment: 84
  • Start: October 2011
  • Completion: December 2014
  • Last verified: May 2015

Study Schematic 

(Coming soon)


Last Editorial review: July 2, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.

Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar